Results 81 to 90 of about 983 (198)

Sleep Disorders in Adults with Prader-Willi Syndrome: Review of the Literature and Clinical Recommendations Based on the Experience of the French Reference Centre [PDF]

, 2022
Prader–Willi syndrome (PWS) is a rare, genetic, multisymptomatic, neurodevelopmental disease commonly associated with sleep alterations, including sleep-disordered breathing and central disorders of hypersomnolence.
Alice Bellicha, Christine Poitou, Federica Sanapo, Isabelle Arnulf, Muriel Coupaye, Pauline Dodet, Smaranda Leu-Semenescu, Stefania Redolfi   +7 more
core   +1 more source

0763 Effects Of Solriamfetol On Driving Performance In Participants With Narcolepsy [PDF]

Sleep, 2020
Abstract Introduction Patients with narcolepsy have an increased risk of automobile accidents. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the US (Sunosi®) for adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75-150 mg/day). This study evaluated
Vinckenbosch, F., Lammers, G., Overeem, S., Chen, D., Wang, G., Carter, L., Zhou, K., Ramaekers, J., Vermeeren, A.   +8 more
openaire   +2 more sources

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns

Nature and Science of Sleep, 2020
Emily C Barker,1 Julie Flygare,2 Shalini Paruthi,3,4 Katherine M Sharkey5– 7 1Case Western Reserve University School of Medicine, Department of Pediatrics, Cleveland, OH, USA; 2Project Sleep, Los Angeles, CA, USA; 3Sleep Medicine and Research ...
Barker EC, Flygare J, Paruthi S, Sharkey KM   +3 more
doaj  

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review

Brain and Behavior, Volume 15, Issue 12, December 2025.
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings, Khalil El Abdi, Fazeela Bibi, Bilal Aslam, Milka Rosario Nuñez, Muhammad Tahla Rehman Sherani, Sujeet Shadmani, Umama Alam, Vohra Maham Hassan, Hoor‐e‐Ainaa, Hania Imran, James Hanna, Said Hamid Sadat   +12 more
wiley   +1 more source

Narcolepsy 2025 (with an Australasian perspective)

Internal Medicine Journal, Volume 55, Issue 11, Page 1805-1813, November 2025.
Abstract Narcolepsy is a disorder of central hypersomnolence, which, while uncommon, can carry profound implications for affected individuals. Despite this, it remains under‐recognised within the medical community and presents frequent diagnostic and treatment challenges in the Australasian setting.
Amelia Lin, Brendon J Yee, Jian Eu Tai, Sheila Sivam   +3 more
wiley   +1 more source

Solriamfetol for attention deficit hyperactivity disorder [PDF]

CNS Spectrums, 2021
Ahmed, Naguy, Adel, El-Sheshaie, Dalal H, Elsori, Bibi, Alamiri   +3 more
openaire   +2 more sources

Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers

Brain and Behavior, Volume 15, Issue 10, October 2025.
Orexin deficiency drives narcolepsy Type 1, leading to excessive daytime sleepiness, cataplexy, and REM intrusions. This review highlights recent advances (2023–2025) in molecular mechanisms, diagnostics, and emerging orexin‐targeted therapies with the potential for disease modification.
Rameesha Rauf, Salwa Asif, Abdallah AlSaafeen, Kaviprada Geathaa Dhantapaani, Maryam Muhammad Nadeem, Zohra Kamran Rao, Aliya Shaju Shahul Hameed, Karthik Chintharala, Muhammad Faheem Anwar, Asad Ali Ahmed Cheema   +9 more
wiley   +1 more source

Present and Future of Central Disorders of Hypersomnolence

Journal of Sleep Research, Volume 34, Issue 5, October 2025.
ABSTRACT Central disorders of hypersomnolence (CDH) are rare neurological conditions lumped by excessive daytime sleepiness (EDS) as primary complaint mostly arising at young age, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and Kleine‐Levin syndrome (KLS). Advances in clinical and translational research have
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary

Postgraduate medicine
Plain Language Summary What is this summary about? The SHARP study looked at the effects of a medication called solriamfetol in people with obstructive sleep apnea (sleep apnea for short) who were very sleepy during the day (called excessive daytime ...
E. Leary, H. V. Van Dongen, Christopher L. Drake, Richard K. Bogan, J. Jaeger, C. Streicher, H. Tabuteau   +6 more
semanticscholar   +1 more source